Contact this trialFirst, we need to learn more about you.
PD-1 Inhibitor
Nivolumab + Ruxolitinib for Hodgkin's Lymphoma
Recruiting1 awardPhase 1 & 2
Minneapolis, Minnesota
This trial is testing a new cancer drug, given with another drug that is already used to treat cancer. The goal is to find the highest dose of the new drug that is still safe, and to see how well it works in patients with a certain type of cancer that has come back or does not respond to other treatments.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.